Prediction of Micrometastasis (< 1 cm) to Pelvic Lymph Nodes in Prostate Cancer: Role of Preoperative MRI
- PMID: 26295669
- DOI: 10.2214/AJR.14.14138
Prediction of Micrometastasis (< 1 cm) to Pelvic Lymph Nodes in Prostate Cancer: Role of Preoperative MRI
Abstract
Objective: The purpose of this study was to retrospectively investigate whether preoperative MRI plays a key role in clinical prediction of micrometastasis (< 1 cm) to pelvic lymph nodes in prostate cancer.
Materials and methods: One hundred one patients with prostate cancer who underwent preoperative MRI and radical prostatectomy with pelvic lymph node dissection were included. None of the patients had a pelvic lymph node with a short-axis diameter of 1 cm or larger on MRI. Both clinical (prostate-specific antigen, biopsy Gleason score, greatest percentage of biopsy core, and percentage of positive cores) and MRI parameters (tumor apparent diffusion coefficient and tumor staging) were assessed. The univariate, multivariate, and ROC curve analyses were conducted.
Results: Of 101 patients, nine (8.9%) had pelvic lymph node metastases. In univariate analysis, all of the clinical and MRI parameters were related to micrometastasis to pelvic lymph nodes (p < 0.05). However, multivariate analysis revealed that only preoperative MRI stage was significant (p = 0.044). AUC of preoperative MRI stage was 0.954 (odds ratio, 21.7). Respective sensitivity and specificity of preoperative tumor staging by MRI were 100% and 65.2% with cutoff of T3a or more, and 88.9% and 94.6% with cutoff of T3b for predicting micrometastasis to pelvic lymph nodes.
Conclusion: Preoperative MRI staging may play a role in prediction of micrometastasis (< 1 cm) to pelvic lymph nodes in prostate cancer.
Keywords: MRI; lymph node metastasis; micrometastasis; prostate cancer; tumor staging.
Similar articles
-
Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer.AJR Am J Roentgenol. 2006 Mar;186(3):743-8. doi: 10.2214/AJR.04.1682. AJR Am J Roentgenol. 2006. PMID: 16498101
-
External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.Urol Int. 2013;90(3):277-82. doi: 10.1159/000343993. Epub 2012 Dec 22. Urol Int. 2013. PMID: 23296120
-
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.J Urol. 2003 Nov;170(5):1798-803. doi: 10.1097/01.ju.0000091805.98960.13. J Urol. 2003. PMID: 14532779
-
Indications for pelvic lymphadenectomy in prostate cancer.Urol Clin North Am. 2001 Aug;28(3):491-8. doi: 10.1016/s0094-0143(05)70157-9. Urol Clin North Am. 2001. PMID: 11590808 Review.
-
[Application of sentinel lymph node tracer techniques in prostate caner].Zhonghua Nan Ke Xue. 2016 Sep;22(9):850-855. Zhonghua Nan Ke Xue. 2016. PMID: 29071886 Review. Chinese.
Cited by
-
How To Manage T3b Prostate Cancer in the Contemporary Era: Is Radiotherapy the Standard of Care?Eur Urol Open Sci. 2023 May 29;53:60-62. doi: 10.1016/j.euros.2023.05.009. eCollection 2023 Jul. Eur Urol Open Sci. 2023. PMID: 37287636 Free PMC article. No abstract available.
-
Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer.Transl Androl Urol. 2018 Sep;7(Suppl 4):S453-S461. doi: 10.21037/tau.2018.05.15. Transl Androl Urol. 2018. PMID: 30363485 Free PMC article. Review.
-
Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy.World J Urol. 2019 Feb;37(2):221-234. doi: 10.1007/s00345-018-2360-1. Epub 2018 Jun 9. World J Urol. 2019. PMID: 29948044 Review.
-
Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection.Eur Radiol. 2018 May;28(5):1969-1976. doi: 10.1007/s00330-017-5229-6. Epub 2017 Dec 21. Eur Radiol. 2018. PMID: 29270644
-
Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer.Curr Treat Options Oncol. 2024 Jan;25(1):66-83. doi: 10.1007/s11864-023-01162-4. Epub 2024 Jan 3. Curr Treat Options Oncol. 2024. PMID: 38212510 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical